Vasculitis & polymyalgia rheumatica
Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicentre real-world study
Authors' conclusion
The GCs' sparing effect of avacopan was confirmed, even in patients with severe kidney vasculitis
Study context
- Population
- Patients with AAV and contraindication to high-dose GCs receiving avacopan via the French early access program, 2020–2023 (median age 72 years)30 with kidney vasculitis
- Participants
- 31 patients
- Outcome
- Favourable outcome and no severe adverse event (single group, avacopan 30 mg b.i.d plus standard of care)
Methodological detailsmulticentre, real-world, French early access program
- Multicentre
- Real-world
- French early access program
Main finding
As reported in the abstract
Patients with a favourable outcome and no severe adverse event, despite rapid GC tapering
25 patients
81%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| ANCA remaining positive · month 12 | Avacopan 55.5% |
- Anti-neutrophil cytoplasm antibodies (ANCA) remaining positive: 10/18 patients
eGFR, baseline to month 12
- eGFR increased from 19 [15; 34] to 35 mL/min/1.73 m² [23; 45] (P < 0.05), independently of kidney biopsy findings
Refractory AAV or relapse while receiving avacopan
- Refractory AAV
- 1
- Relapse
- 2
Safety
| Outcome | Values |
|---|---|
| Severe adverse events leading to avacopan withdrawal (hepatitis and age-related macular degeneration) | Avacopan 2 events |
Original publication
Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicentre real-world study. Rheumatology (Oxford). Published 13 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →